Compare · KIN vs SBBP
KIN vs SBBP
Side-by-side comparison of Kindred Biosciences, Inc. (KIN) and Strongbridge Biopharma plc (SBBP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KIN and SBBP operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- KIN is the larger of the two at $420.5M, about 3.1x SBBP ($136.0M).
- Company
- Kindred Biosciences, Inc.
- Strongbridge Biopharma plc
- Price
- $9.25+0.00%
- $2.00+1.78%
- Market cap
- $420.5M
- $136.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2013
- 2015
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 0
Kindred Biosciences, Inc.
Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; KIND-025 a canine fusion protein targeting IL-4 and IL-13 for atopic dermatitis in dogs; KIND-030, a monoclonal antibody targeting canine parvovirus for the prophylactic indication in dogs; KIND-509, an antibody for canine inflammatory bowel disease in dogs; KIND-510a, a long-acting feline recombinant erythropoietin being developed for the management of non-regenerative anemia in cats; and KIND-511, an anti-tumor necrosis factor treatment for newborn foals. The company was incorporated in 2012 and is headquartered in Burlingame, California.
Strongbridge Biopharma plc
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that has completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.
Latest KIN
- TCW Special Purpose Acquisition Corp. Appoints Nanxi Liu to Board of Directors
- SEC Form SC 13G/A filed by Kindred Biosciences, Inc. (Amendment)
- SEC Form 4 filed by Park West Asset Management Llc
- SEC Form 15-12B filed by Kindred Biosciences, Inc.
- SEC Form EFFECT filed by Kindred Biosciences, Inc.
- SEC Form SC 13D/A filed by Kindred Biosciences, Inc. (Amendment)
- SEC Form 4: Chin Richard returned $15,884,757 worth of Common Stock to the company (1,717,271 units at $9.25), closing all direct ownership in the company
- SEC Form 4: Wee Wendy returned $727,170 worth of Common Stock to the company (78,613 units at $9.25), closing all direct ownership in the company
- SEC Form 4: Bevers Denise returned $1,348,974 worth of Common Stock to the company (145,835 units at $9.25), closing all direct ownership in the company
- SEC Form 4: Zhan Hangjun returned $594,830 worth of Common Stock to the company (64,306 units at $9.25), closing all direct ownership in the company
Latest SBBP
- SEC Form SC 13D/A filed by Strongbridge Biopharma plc (Amendment)
- SEC Form 4: Cdk Associates, L.L.C. disposed of 8,060,682 units of Ordinary Shares
- SEC Form SC 13D/A filed by Strongbridge Biopharma plc (Amendment)
- SEC Form 15-12B filed by Strongbridge Biopharma plc
- SEC Form EFFECT filed by Strongbridge Biopharma plc
- SEC Form EFFECT filed by Strongbridge Biopharma plc
- SEC Form EFFECT filed by Strongbridge Biopharma plc
- SEC Form 4: Wilhoit Scott L. returned 109,510 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Kollender Richard S returned 234,229 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Cohen Fredric J. returned 160,408 units of Ordinary Shares to the company, decreasing direct ownership by 50% to 160,408 units